Efficacy and safety of co-administered once-weekly cagrilintide 2·[amount hidden] with once-weekly semaglutide 2·[amount hidden] in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Plain-language guide to PMID 37364590 (2023): double-blind randomized controlled trial study of Cagrilintide and Semaglutide.

Key Facts

PMID: 37364590
Journal: Lancet (London, England)
Year: 2023
Study type: Randomized Controlled Trial
Authors: Frias JP et al. (9 authors)
DOI: 10.1016/S0140-6736(23)01163-7

What This Study Did, in Plain Language

What Was Tested

Researchers studied Cagrilintide and Semaglutide in this randomized controlled trial publication.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Randomisation was done centrally using an interactive web response system and was stratified according to use of SGLT2 inhibitor treatment (yes vs no).

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

Because people in this Cagrilintide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Cagrilintide.

More than one site took part, so the participants came from several places.

This 32-week, multicentre, double-blind, phase 2 trial was conducted across 17 sites in the USA.

The primary endpoint was change from baseline in HbA1c; secondary endpoints were bodyweight, fasting plasma glucose, continuous glucose monitoring (CGM) parameters, and safety.

This trial is registered on ClinicalTrials.gov (NCT04982575) and is complete.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Islet Amyloid Polypeptide, Hypoglycemic Agents, Sodium-Glucose Transporter 2 Inhibitors, Blood Glucose, Blood Glucose Self-Monitoring and Glucagon-Like Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Cagrilintide and Semaglutide.

Results are reported in around 12 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Lancet (London, England)), a journal based in England.

More context: the Cagrilintide compound page and the Semaglutide compound page, all human trials.

Our Notes on the Compounds

Cagrilintide: An investigational long-acting amylin analog; CagriSema combines it with semaglutide.

Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).

Amylin (Islet Amyloid Polypeptide): A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.